Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 9:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Bridging Therapy Clear all
Recruiting Phase 4 Interventional

Preoperative BOTOX® Injection for Large Ventral Hernia Repair

NCT07220382
View directory record Official record
Conditions
Hernia Abdominal Wall, Botox Injection, Hernia Incisional Ventral, Hernia Repair With Compartment Syndrome, Hernia Surgery, Hernia, Hernia Incisional
Interventions
OnabotulinumtoxinA Injection, Saline (placebo) Injection, OnabotulinumtoxinA, 0.9 % Normal Saline, Open Ventral Hernia Repair
Procedure · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 22, 2026, 9:12 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Treatment Response in Schizophrenia: Bridging Imaging and Postmortem Studies

NCT00937716
View directory record Official record
Conditions
Schizophrenia
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 55 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 25, 2021 · Synced Sep 22, 2026, 9:12 AM EDT
Recruiting Phase 1 Interventional

LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

NCT05990465
View directory record Official record
Conditions
Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Burkitt Lymphoma
Interventions
Pirtobrutinib, LV20.19 CAR T cells
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 81 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 22, 2026, 9:12 AM EDT
Completed No phase listed Observational

Sacroiliac (SI) Joint Transfixing and Fusion: Meaningful Long Term Outcomes With Nevro1

NCT06909292
View directory record Official record
Conditions
Sacroiliac Joint Dysfunction
Interventions
Sacroiliac Joint transfixing and fusion system (Nevro1)
Device
Lead sponsor
Nevro Corp
Industry
Eligibility
21 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
5
States / cities
Lodi, California • Southfield, Michigan • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 22, 2026, 9:12 AM EDT
Completed Not applicable Interventional

A Randomized Clinical Study of a Mind-Body Approach to Domestic Violence Offender Treatment

NCT00983593
View directory record Official record
Conditions
Domestic Violence, Intimate Partner Violence
Interventions
Mind-Body Bridging
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Sep 22, 2026, 9:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Bridging the Docosahexaenoic Acid (DHA) Gap: The Effects of Omega-3 Fatty Acid Supplementation in Premature Infants

NCT01908907
View directory record Official record
Conditions
Prematurity
Interventions
DHA oil, (MCT) Control oil
Dietary Supplement
Lead sponsor
Sanford Health
Other
Eligibility
24 Weeks to 33 Weeks
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Sep 22, 2026, 9:12 AM EDT
Recruiting Not applicable Interventional

Evaluation of Branch Endografts in the Treatment of Aortic Aneurysms

NCT01524211
View directory record Official record
Conditions
Thoracoabdominal Aortic Aneurysm, Aortic Arch Aneurysm
Interventions
Zenith® t-Branch, Terumo Arch Branch
Device
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2032
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 22, 2026, 9:12 AM EDT
Completed Not applicable Interventional

Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)

NCT06004167
View directory record Official record
Conditions
Lymphoma, B-Cell, Relapsed Cancer, Refractory Lymphoma, Diffuse Large B Cell Lymphoma, Mediastinal Large B-cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma
Interventions
Adaptive Bridging Radiation Therapy (ABRT)
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 22, 2026, 9:12 AM EDT
Completed Phase 4 Interventional Results available

A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic

NCT03235154
View directory record Official record
Conditions
Hepatitis C, Chronic, Hepatitis C, Opiate Dependence
Interventions
sofosbuvir/velpatasvir
Drug
Lead sponsor
Community Research Initiative of New England
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Somerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 22, 2026, 9:12 AM EDT
Recruiting Phase 1 Interventional

Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma

NCT07093554
View directory record Official record
Conditions
Relapse Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Talquetamab, Ciltacabtagene Autoleucel
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Sep 22, 2026, 9:12 AM EDT
Completed Not applicable Interventional Results available

The Insulin-Only Bionic Pancreas Bridging Study- Pediatric Transitional Study

NCT04112069
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog, Usual Care
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Palo Alto, California • Aurora, Colorado • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 22, 2026, 9:12 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma

NCT03430011
View directory record Official record
Conditions
Multiple Myeloma
Interventions
JCARH125, JCARH125 + anakinra
Biological
Lead sponsor
Juno Therapeutics, a Subsidiary of Celgene
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
20
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Sep 22, 2026, 9:12 AM EDT
Terminated Phase 1 Interventional Results available

Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma

NCT03318861
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
KITE-585, Cyclophosphamide, Fludarabine
Genetic · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
9
States / cities
Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Sep 22, 2026, 9:12 AM EDT
Terminated Phase 2 Interventional Results available

Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy (PEA Bridging Study)

NCT03273257
View directory record Official record
Conditions
Chronic Thromboembolic Pulmonary Hypertension, CTEPH
Interventions
Riociguat, Placebo, Pulmonary endarterectomy
Drug · Procedure
Lead sponsor
International CTEPH Association
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Sep 22, 2026, 9:12 AM EDT
Recruiting Phase 4 Interventional

The Bridging Antiplatelet Therapy With Cangrelor 2 Study

NCT07225842
View directory record Official record
Conditions
Coronary Arterial Disease (CAD)
Interventions
Cangrelor
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 22, 2026, 9:12 AM EDT
Terminated Phase 2 Interventional Results available

Blinatumomab Bridging Therapy for BALL

NCT04556084
View directory record Official record
Conditions
B-cell Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia
Interventions
Blinatumomab
Drug
Lead sponsor
Michael Burke
Other
Eligibility
Up to 25 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Sep 22, 2026, 9:12 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring

NCT05777174
View directory record Official record
Conditions
Kidney Diseases, Kidney Injury, Kidney Failure
Interventions
MB-102, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
Drug · Device
Lead sponsor
MediBeacon
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
5
States / cities
Chicago, Illinois • Columbus, Ohio • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Sep 22, 2026, 9:12 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Network-Based Support to Help Community Coalition Members Choose and Use Strategies to Improve Child Health

NCT07804550
View directory record Official record
Conditions
Childhood Obesity, Evidence-Based Practice, Food Systems, Food Policy
Interventions
Catalyzing Communities, FICAS Implementation Intervention
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
3,300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 22, 2026, 9:12 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

NCT04150913
View directory record Official record
Conditions
Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma, Neurotoxicity, Neurotoxicity Syndromes, Cytokine Release Syndrome
Interventions
Anakinra, Axicabtagene Ciloleucel
Drug
Lead sponsor
Marcela V. Maus, M.D.,Ph.D.
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 22, 2026, 9:12 AM EDT
Suspended Phase 3 Interventional Accepts healthy volunteers

Buprenorphine for Probationers and Parolees: Bridging the Gap Into Treatment

NCT03616236
View directory record Official record
Conditions
Opioid Use
Interventions
Buprenorphine/Naloxone, Treatment as usual
Drug · Other
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 22, 2026, 9:12 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients

NCT02445248
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma (DLBCL)
Interventions
Tisagenlecleucel, Lymphodepleting chemotherapy
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
12
States / cities
San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Sep 22, 2026, 9:12 AM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers

NCT07544589
View directory record Official record
Conditions
Colorectal Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Adenocarcinoma
Interventions
DISP-10
Biological
Lead sponsor
Dispatch Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2046
U.S. locations
5
States / cities
Duarte, California • Newport Beach, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 22, 2026, 9:12 AM EDT
Completed Not applicable Interventional Results available

Evaluating the Ease of Use of a VAC GranuFoam Bridge Dressing on Diabetic Foot Ulcers Receiving VAC Negative Pressure Wound Therapy

NCT00847730
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
V.A.C. Negative Pressure Wound Therapy System
Device
Lead sponsor
KCI USA, Inc
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
6
States / cities
New Haven, Connecticut • South Miami, Florida • Bethlehem, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Sep 22, 2026, 9:12 AM EDT
Completed Not applicable Interventional Results available

Restoration of Cognitive Function With TDCS and Training in Serious Mental Illness

NCT03208036
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Schizo Affective Disorder
Interventions
TDCS, Sham Stimulation, Cognitive Remediation, Bridging Group
Device · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Sep 22, 2026, 9:12 AM EDT